StockData
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Guardant Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)

Close on Oct 19, 2026

Market cap
$20.98B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 28, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026After market close$335.00M$-0.90$-0.42
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$301.70M$-0.85$-0.45
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026Before market open$280.00M––
Q3 FY2025
Ended Sep 30, 2025
Oct 29, 2025After market close$265.20M$-0.74$-0.39
Q2 FY2025
Ended Jun 30, 2025
Jul 30, 2025After market close$232.10M$-0.80$-0.44
Q1 FY2025
Ended Mar 31, 2025
Apr 30, 2025After market close$203.50M$-0.77$-0.49
Q4 FY2024
Ended Dec 31, 2024
Jan 13, 2025After market close$200.00M––
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024After market close$191.50M$-0.88$-0.45
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024After market close–––

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
free cash flow burnfull-year$195.00M to $205.00MRaised
non-GAAP gross marginnon-GAAPfull year 202664% to 65%Maintained
Shield volume2026270,000 to 285,000Raised
Oncology revenue growth202630% growthRaised
Oncology volume growth202650% growthRaised
total non-GAAP operating expensesnon-GAAP2026$1.08B to $1.10BRaised
revenue growthfull year 202636% to 38% growthRaised
revenuefull year 2026$1.34B to $1.36BRaised
Screening revenue2026$218.00M to $230.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Guardant Health filed with the SEC